Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
A 67-year-old man with acute myeloid leukemia (AML) was treated with low-dose decitabine. He achieved a complete remission (CR) after two cycles of therapy, and he remained in remission during 1 year of treatment. He developed recurrent AML after discontinuation of decitabine. He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine.
Cashen
Amanda F
AF
Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, St. Louis, Missouri, USA. acashen@im.wustl.edu
Devine
Hollie
H
DiPersio
John
J
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077209:Decitabine; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000517:prevention & control*; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors
D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine